Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
– Primary and secondary endpoints met with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose groups –
– Sustained activity with rapid onset within 2 weeks –
– Similar improvement in omalizumab-experienced/refractory and omalizumab-naïve disease consistent with unique mechanism of action –
– Favorable safety profile –
– 52 week results and Phase 3 CSU trial initiations anticipated in 2024 –
– Company to host webcast February 25th at 9:45 am ET-